Upfront Briefing
Lilly's retatrutide hit Phase 3 in obesity with up to 30.3% mean weight loss at 80 weeks, resetting the bar in the GLP-1 race and putting Novo, Roche and Structure firmly on the defensive.
Elsewhere, Biogen and Denali binned BIIB122 after a Parkinson's miss, Regeneron's Otarmeni gene therapy was accepted for EMA review, and Retro Biosciences pegged a fresh round at a $1.8 billion valuation.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,445.7 |
0.2% |
8.6% |
| Nasdaq 100 |
29,357.3 |
0.2% |
16.5% |
| Russell 2000 |
2,843.4 |
0.9% |
13.4% |
| Healthcare (XLV) |
148.1 |
0.7% |
(4.7%) |
| Biotech (XBI) |
132.8 |
0.8% |
9.3% |
| Nasdaq Biotech (NBI) |
5,901.6 |
0.7% |
3.4% |
| Clinical Trials (BBC) |
43.3 |
2.0% |
15.2% |
|
- Risk-on tape, broadly speaking: small caps outpaced the majors as the Russell 2000 rose +0.9%, extending the market's positive tilt into the week.
- Biotech kept pace with defensives as XBI (+0.8%) edged XLV (+0.7%), even with stock-specific pipeline risk in the headlines after Biogen and Denali's BIIB122 miss.
- Market data: US close Thursday 21-May-2026.
The Big 3
|
1
|
Lilly's retatrutide hits Phase 3 in obesity with up to 30.3% weight loss
|
- Lilly's TRIUMPH-1 Phase 3 study of retatrutide — a first-in-class GIP/GLP-1/glucagon triple agonist — hit primary and key secondaries at all three doses, delivering up to 30.3% mean weight loss at 12 mg vs 2.2% on placebo at 80 weeks; 65.3% of 12 mg patients hit a BMI <30.
- Why it matters: Retatrutide resets the efficacy bar above Zepbound and well above Wegovy, extending Lilly's franchise lead and raising the hurdle for Novo, Roche and Structure. Seven more TRIUMPH readouts due across 2026 (T2D, CV, OA, OSA, MASH) — strategic tailwind for LLY, derating risk for sub-scale obesity assets.
- Source: BioPharma Dive; PR
|
|
2
|
Biogen, Denali halt BIIB122 after Phase 2b LUMA miss
|
- Biogen and Denali stopped BIIB122 (LRRK2 inhibitor) in idiopathic Parkinson's after the 648-patient Phase 2b LUMA study failed. Closely watched program is off the board for both pipelines.
- Why it matters: Removes a late-stage neuro asset and concentrates Denali's value case on the LRRK2-mutation BEACON readout in 1H27, where genetic enrichment may improve odds — but program risk and Biogen's neuro pipeline depth are now back under scrutiny.
- Source: Fierce Biotech
- More: STAT; PR
|
|
3
|
Regeneron's Otarmeni accepted for EMA review in OTOF hearing loss
|
- EMA accepted Regeneron's Otarmeni (lunsotogene parvec) MAA under Accelerated Assessment for biallelic OTOF-related hearing loss — already FDA-approved in April 2026, supported by CHORD where 80% met the primary endpoint and 42% achieved normal hearing on longer follow-up.
- Why it matters: Ultra-rare population (~46 EU newborns/year) and Regeneron's free-in-US pricing mean direct revenue is modest — the real read-through is platform validation for Regeneron's genetic medicines engine and an EU-first precedent for AAV-based neurosensory restoration.
- Source: PR
|
Everything Else that broke
- Regeneron's Lynozyfic (linvoseltamab) monotherapy delivered 100% hematologic CR at the highest tested dose in 2L+ systemic AL amyloidosis, supporting label-expansion potential beyond multiple myeloma. — PR
- Endpoints exclusive details the covert biotech-led campaign that pressured former FDA Commissioner Marty Makary out earlier this month. — Endpoints
- China's NMPA approves Boehringer Ingelheim's HERNEXEOS (zongertinib) as first-line oral targeted therapy for HER2-mutant advanced NSCLC — 75.7% ORR in treatment-naïve patients. — PR
- Merck partner Kelun-Biotech reports its Phase 3 sac-TMT (TROP2 ADC) study in NSCLC cut tumor progression risk by 65%; two registrational studies selected for ASCO oral session. — PR
- OSE Immunotherapeutics posts positive Phase 2 TEDOVA topline with Tedopi (neoepitope cancer vaccine) in recurrent ovarian cancer. — PR
- Innovent's IBI363 (PD-1/IL-2 bispecific) posts encouraging first-line + chemo POC data and durable long-term survival in immunotherapy-resistant NSCLC ahead of ASCO. — PR
- BioNTech outlines progress across its late-stage oncology pipeline at ASCO 2026, with focus on PD-L1×VEGF bispecific BNT327 — a key competitive read vs Summit/Akeso. — PR
- Mabwell to present new oral + poster data on Nectin-4 ADC 9MW2821 at ASCO — adds to the active Nectin-4 ADC competitive set. — PR
- Amgen names Thomas Dittrich CFO as Peter Griffith retires — second senior departure after CSO David Reese earlier this year. — Endpoints
- Assembly Biosciences expands ABI-6250 clinical development into cholestatic liver diseases, broadening the asset's TAM beyond its initial indication. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Avista Healthcare Partners and Damier Group sign a definitive agreement to acquire Germany-based Sanotact Group, a vitamins/minerals/supplements CDMO and branded VMS platform — consumer-health PE rollup rather than a drug deal. — PR
VC / Private Financings
- Retro Biosciences (San Francisco; longevity / autophagy + cell reprogramming): new round closed at a $1.8B post-money valuation, led by Sam Altman with participation from family offices, sovereign wealth funds and longevity-focused VCs. Lead asset is an autophagy-enhancing oral therapy currently in a Phase 1 Alzheimer's trial, with first data expected ~August 2026. — STAT
- 20n Bio (AI-enabled cyclic peptide platform): $7.5M Seed+ led by Charles River Laboratories with participation from o2h Ventures; round extends platform development and advances therapeutic pipeline. — BioSpace
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours.
Academic Corner - Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. — Nature Medicine
- AI-guided redesign of laboratory-evolved reverse transcriptases enhances prime editing. — Nature Biotech
- Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. — Lancet
|
